Coskun U - Search Results

1

Mammary tumor heterogeneity in the expansion of myeloid-derived suppressor cells.

Donkor MK, Lahue E, Hoke TA, Shafer LR, Coskun U, Solheim JC, Gulen D, Bishay J, Talmadge JE. Donkor MK, et al. Among authors: coskun u. Int Immunopharmacol. 2009 Jul;9(7-8):937-48. doi: 10.1016/j.intimp.2009.03.021. Epub 2009 Apr 9. Int Immunopharmacol. 2009. PMID: 19362167

2

Closing the manufacturing process of dendritic cell vaccines transduced with adenovirus vectors.

Gulen D, Abe F, Maas S, Reed E, Cowan K, Pirruccello S, Wisecarver J, Warkentin P, Northam M, Turken O, Coskun U, Senesac J, Talmadge JE. Gulen D, et al. Among authors: coskun u. Int Immunopharmacol. 2008 Dec 20;8(13-14):1728-36. doi: 10.1016/j.intimp.2008.08.010. Epub 2008 Sep 13. Int Immunopharmacol. 2008. PMID: 18793758

3

Serum P-selectin, soluble vascular cell adhesion molecule-I (s-VCAM-I) and soluble intercellular adhesion molecule-I (s-ICAM-I) levels in bladder carcinoma patients with different stages.

Coskun U, Sancak B, Sen I, Bukan N, Tufan MA, Gülbahar O, Sozen S. Coskun U, et al. Int Immunopharmacol. 2006 Apr;6(4):672-7. doi: 10.1016/j.intimp.2005.10.009. Epub 2005 Nov 28. Int Immunopharmacol. 2006. PMID: 16504931

4

Serum big endothelin-1 levels in female patients with breast cancer.

Yildirim Y, Gunel N, Coskun U, Sancak B, Bukan N, Aslan S, Cetin A. Yildirim Y, et al. Among authors: coskun u. Int Immunopharmacol. 2008 Aug;8(8):1119-23. doi: 10.1016/j.intimp.2008.03.023. Epub 2008 Apr 28. Int Immunopharmacol. 2008. PMID: 18550016

5

Serum M30 levels are associated with survival in advanced gastric carcinoma patients.

Yaman E, Coskun U, Sancak B, Buyukberber S, Ozturk B, Benekli M. Yaman E, et al. Among authors: coskun u. Int Immunopharmacol. 2010 Jul;10(7):719-22. doi: 10.1016/j.intimp.2010.03.013. Epub 2010 Mar 31. Int Immunopharmacol. 2010. PMID: 20362077

6

Elevated serum levels of M30 and M65 in patients with locally advanced head and neck tumors.

Ozturk B, Coskun U, Sancak B, Yaman E, Buyukberber S, Benekli M. Ozturk B, et al. Among authors: coskun u. Int Immunopharmacol. 2009 May;9(5):645-8. doi: 10.1016/j.intimp.2009.02.004. Epub 2009 Feb 26. Int Immunopharmacol. 2009. PMID: 19249390

7

Prognostic importance of markers for inflammation, angiogenesis and apoptosis in high grade glial tumors during temozolomide and radiotherapy.

Demirci U, Yaman M, Buyukberber S, Coskun U, Baykara M, Uslu K, Ozet A, Benekli M, Bagriacik EU. Demirci U, et al. Among authors: coskun u. Int Immunopharmacol. 2012 Dec;14(4):546-9. doi: 10.1016/j.intimp.2012.08.007. Epub 2012 Aug 29. Int Immunopharmacol. 2012. PMID: 22940539

8

Serum interleukin-18 and nitric oxide activity in bladder carcinoma.

Bukan N, Sözen S, Coskun U, Sancak B, Günel N, Bozkirli I, Senocak C. Bukan N, et al. Among authors: coskun u. Eur Cytokine Netw. 2003 Jul-Sep;14(3):163-7. Eur Cytokine Netw. 2003. PMID: 14656691 Free article.

9

Serum levels of interleukin-18 and nitrite+nitrate in renal cell carcinoma patients with different tumor stage and grade.

Sözen S, Coskun U, Sancak B, Bukan N, Günel N, Tunc L, Bozkirli I. Sözen S, et al. Among authors: coskun u. Neoplasma. 2004;51(1):25-9. Neoplasma. 2004. PMID: 15004655

10

Serum YKL-40 levels as a prognostic factor in patients with locally advanced breast cancer.

Yamac D, Ozturk B, Coskun U, Tekin E, Sancak B, Yildiz R, Atalay C. Yamac D, et al. Among authors: coskun u. Adv Ther. 2008 Aug;25(8):801-9. doi: 10.1007/s12325-008-0082-2. Adv Ther. 2008. PMID: 18670741

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

298 results

Search Page

Filters